Sunday, November 5, 2017
- 9:00AM-11:00AM
-
Abstract Number: 465
Basement Membrane Remodeling in Rheumatoid Arthritis Associates with Disease Activity, Response to IL-6 Inhibitor Treatment and Radiographic Progression: Analysis of Two Phase III Clinical Trials
Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response- 9:00AM-11:00AM
-
Abstract Number: 540
Being Elderly Is Not a Predictive Factor of Discontinuation of Abatacept Due to Adverse Events in Rheumatoid Arthritis Patients with Concomitant Methotrexate: A Retrospective Observational Study Based on Data from a Japanese Multicenter Registry Study
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster I: Comorbidities and Adverse Events; Efficacy and Safety of Small Molecules- 9:00AM-11:00AM
-
Abstract Number: 45
BIIB063, a Potent Anti-CD40 Antagonistic Monoclonal Antibody (MAb): Lessons Learned from an Early Development Program.
B Cell Biology and Targets in Autoimmune Disease Poster- 9:00AM-11:00AM
-
Abstract Number: 299
Bik Plays an Important Role of Cell Proliferation Caused By Nitric Oxide in Rheumatoid Arthritis Synovium
Innate Immunity and Rheumatic Disease Poster I- 9:00AM-11:00AM
-
Abstract Number: 307
Biochemical Intervertebral Disc Alterations in Patients with Low Back Pain and Radiculopathy
Orthopedics, Low Back Pain and Rehabilitation Poster- 9:00AM-11:00AM
-
Abstract Number: 572
Biopsy Accuracy in Sjögren’s Syndrome: Analysis of 803 Patients Presenting with Sicca Syndrome Referred to Labial Salivary Gland Biopsy
Sjögren's Syndrome Poster I: Translational Research- 9:00AM-11:00AM
-
Abstract Number: 226
Biopsy Proven Giant Cell Arteritis in African Descent Populations: Incidence and Characteristics in Martinique, French West Indies
Healthcare Disparities in Rheumatology Poster- 9:00AM-11:00AM
-
Abstract Number: 503
BMS-986195 Is a Highly Selective and Rapidly Acting Covalent Inhibitor of Bruton’s Tyrosine Kinase with Robust Efficacy at Low Doses in Preclinical Models of RA and Lupus Nephritis
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster I: Comorbidities and Adverse Events; Efficacy and Safety of Small Molecules- 9:00AM-11:00AM
-
Abstract Number: 514
BMS-986195, a Novel, Rapidly Acting, Covalent Inhibitor of Bruton’s Tyrosine Kinase: Safety, Pharmacokinetic and Pharmacodynamic Profiles in Healthy Participants
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster I: Comorbidities and Adverse Events; Efficacy and Safety of Small Molecules- 9:00AM-11:00AM
-
Abstract Number: 609
Body Mass Index Does Not Influence the Efficacy of Subcutaneous Abatacept in Patients with Psa: Results from a Phase III Trial
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I- 9:00AM-11:00AM
-
Abstract Number: 22
Bone Regulatory Cytokine Production By B Cells in Rheumatoid Arthritis Is Dependent on NF-κb Activation and Autophagy Pathways
B Cell Biology and Targets in Autoimmune Disease Poster- 9:00AM-11:00AM
-
Abstract Number: 29
BTK Inhibition Ameliorates Lupus-Associated Neuropsychiatric and Skin Disease
B Cell Biology and Targets in Autoimmune Disease Poster- 9:00AM-11:00AM
-
Abstract Number: 3
Burden of Antiphospholipid Syndrome in a Thromboembolic Disease Registry
Antiphospholipid Syndrome Poster- 9:00AM-11:00AM
-
Abstract Number: 364
Canakinumab First or Second Choice in Systemic Juvenile Idiopathic Arthritis – Experience from Clinical Practice